Why intervention in secondary MR does not fix the ventricle
TEER or mitral valve intervention in secondary MR can reduce regurgitant volume and improve symptoms and HF hospitalizations in selected patients. But it does not directly treat the underlying cardiomyopathy, LV remodeling, or atrial remodeling. Understanding this distinction shapes how we frame goals, risks, and expectations.
A patient with severe secondary MR and LVEF of 28% undergoes TEER. The MR is reduced from severe to mild-moderate. Six months later, LVEF is 30%. The patient feels somewhat better but remains in NYHA Class III. Was the intervention successful? It depends on what you mean by success. Procedurally, it may have succeeded. But TEER treated the regurgitation — not the ventricle.
Key takeaway
In secondary MR, the mitral valve leak is a consequence of LV or atrial remodeling, not the primary problem. Reducing MR can lower left atrial pressure, reduce pulmonary venous congestion, and improve symptoms and HF events in selected patients. But TEER or mitral intervention does not directly reverse the cardiomyopathy, erase myocardial scar, or restore normal LV architecture. It is not a cure — it is one component of HF management.
Key points
- Secondary MR is driven by impaired mitral coaptation from LV remodeling (ventricular functional MR) or LA enlargement (atrial functional MR). The leaflets are often not the primary pathology.
- Reducing MR decreases volume load on the failing LV and can lower pulmonary congestion, improving symptoms and potentially reducing HF hospitalizations.
- LVEF does not reliably normalize after TEER. The goal is not LVEF normalization — it is reducing MR-related load and improving symptoms and HF trajectory.
- In COAPT-like patients, TEER added to maximally tolerated GDMT reduced HF hospitalization and mortality — but the underlying cardiomyopathy persisted.
- Perioperatively, a post-TEER secondary MR patient should still be evaluated as a patient with HFrEF. Cardiac reserve depends on LVEF, LV size, RV function, pulmonary hypertension, and GDMT optimization — not MR grade alone.
When to read this
A patient with secondary MR is being considered for TEER or surgical MV intervention. You want to frame expected benefit and limitations for the patient, family, and perioperative team.
What intervention can and cannot do
Reducing MR in secondary MR unloads the failing ventricle from an additional volume burden. This can lower left atrial pressure, reduce pulmonary venous congestion, and improve functional status. In COAPT, carefully selected patients with symptomatic HFrEF and severe secondary MR despite maximally tolerated GDMT had fewer HF hospitalizations and lower mortality when TEER was added to GDMT. These are meaningful clinical outcomes.
But reducing MR does not make the underlying cardiomyopathy disappear. LV scar, dilation, and systolic dysfunction — along with related comorbidities such as pulmonary hypertension and RV dysfunction — may persist. Some patients show LV remodeling improvement after MR reduction, but the response is variable. The main goal of secondary MR intervention is not to normalize LVEF; it is to reduce the additional hemodynamic burden of MR and improve symptoms and HF outcomes. In MITRA-FR, which enrolled a different patient population including more patients with advanced LV dilation relative to MR burden, TEER did not show clear clinical benefit — a contrast that underscores that MR reduction does not help every secondary MR patient equally.
Proportionate vs disproportionate secondary MR
One proposed framework for understanding when MR reduction is likely to help involves asking whether the MR is proportionate or disproportionate to the degree of LV remodeling. In proportionate secondary MR, MR severity is roughly what would be expected given the degree of LV dilation and dysfunction — the LV disease may be the dominant driver of prognosis, and MR reduction may have less impact on the overall HF trajectory. In disproportionate secondary MR, MR severity appears larger than expected for the degree of LV remodeling, suggesting that the valve leakage is adding a substantial additional hemodynamic burden — and reducing it may provide greater benefit.
This framework is not a tool decision criterion in this platform. It requires clinical judgment and Heart Valve Team evaluation integrating symptoms, GDMT status, LV function, pulmonary pressure, RV function, and valve anatomy. It is offered here to explain why two patients labeled 'severe secondary MR' may have different expected responses to intervention.
Perioperative framing
When evaluating a patient with secondary MR pre-operatively, asking 'should the valve be fixed before surgery?' often misframes the problem. More useful questions are: How symptomatic is this patient? What are LVEF and LV size? Is pulmonary pressure elevated? Is RV function preserved? Has GDMT been optimized? Has there been recent HF hospitalization? Could elective surgery wait while HF management is optimized? In secondary MR, the valve is part of the picture — perioperative risk depends on HFrEF substrate, pulmonary hypertension, RV function, systemic condition, and surgical stress.
Procedural success and clinical success are not the same
In secondary MR, procedural success (MR reduced to mild or mild-moderate) is not equivalent to clinical success (symptoms improved, HF hospitalizations reduced, functional capacity and quality of life improved, and in some patients survival improved). The former can be achieved in most TEER procedures. The latter depends on patient selection, GDMT optimization, LV and RV function, pulmonary hypertension, valve anatomy, procedural durability, and residual MR.
Apply this in practice
Use the Secondary MR Intervention Navigator to evaluate the intervention pathway for your patient.
Secondary MR Intervention Navigator